Sign up United Kingdom
OptiBiotix Health plc (LON:OPTI)

OptiBiotix Health plc (LON:OPTI)

Share Price
80.30 p
4.3002 (5.66 %)
Market Cap
£68.97 m
Proactive Investors - Run By Investors For Investors

OptiBiotix Health plc

Facts at a Glance
Three core technology platforms, with diversification into skin in 2016
CEO: Stephen O'Hara
Development programmes:
OptiScreen®: The identification and development of microbial strains (probiotics) which can effect human metabolism and physiology to create a health benefit (e.g. cholesterol, hypertension reduction, diabetes)
OptiBiotix®: The development of...

Market: AIM:OPTI
52-week High/Low: 133.25p / 49.60p
Sector: Health Care, Equipment & Services
Market Cap: 68.97M

OptiBiotix Health plc

Interactive graph

col 3
col 4
col 5
col 6

Big picture - Why invest in OptiBiotix Health plc

OptiBiotix Health plc Snapshot


Welcome to Optibiotix Health PLC

Recent advances in cellular and molecular biology have led to a greater understanding of the strains and functions of bacteria that make up the human microbiome - the collective genome of the microbes in the body - providing greater insight into the role of microbial flora in human health.  An increasing number of scientific studies have now shown that our bacterial flora are influential in the development and aetiology of diseases as diverse as inflammatory bowel disease, autism, atherosclerosis, gastrointestinal cancers and metabolic diseases such as type 1 diabetes and obesity.

The healthy human microbiome contains at least 10,000 microbial species with some eight million different protein-encoding genes, 360 times more genes than the human genome. This metabolically active, rapidly renewable ecosystem makes up over 90% of the cells in the human body and contributes to host immunity, metabolism and  physiology. More importantly this vast and diverse microbial genome is easier to influence than the human genome. This creates the potential to diagnose, prevent or treat disease by modifying the organisms in or on the human  body. 

The prospect of modulating the human microbiome to prevent, manage, and treat human disease has led the human microbiome to be described as one of the most significant scientific breakthroughs of 2013 and one of the top 10 emerging technologies of 2014.

OptiBiotix®Health intends to exploit these recent scientific advances to develop a range of products which can modify the human microbiome and bring specific health benefits.  This will meet a large and growing consumer need for nutritional and effective health care products supported by scientific evidence and clinical studies.  With increasing scientific corroboration of health benefits from products which modify the human microbiome this sector has been predicted to become one of the world’s fastest growth areas in the next 10 years. 

Microbiome Research May Soon Pay Off Big

OptiBiotix’s CEO ‘ Stephen OHara said ‘This publication recognises that research into the human microbiome has given scientists the potential to change the microbiome and the potential this brings to prevent, manage, and treat many diseases.  OptiBiotix is leading this field and looks forward to bringing new products to market to help sufferers with common lifestyle diseases such as heart disease, obesity, and diabetes’. 

Stephen OHara, OptiBiotix CEO said ‘ This new research funding recognises the role of microbiome engineering in human heath and brings new grant funding to support research into the many issues that face developing countries.  The increase in grant funding from the Gates Foundation and others will further support the development of microbiome applications to prevent, manage, and treat human disease’.  

Extreme weight loss surgery works, but is it thanks to the knife—or the microbes?

OptiBiotix’s CEO Stephen OHara said ‘ This is one of a series of recent scientific reports providing evidence for the role of microbial changes in weight loss following bariatric surgery and the ‘cure’ of type 2 diabetes. The implication being that rather than have bariatric (e.g gastric band) surgery you would simply change your microbiome to loose weight and/or ‘cure’ type 2 diabetes.   OptiBiotix is developing microbiome modulators which can change the microbial flora and this creates the potential to reduce weight without the risks and cost associated with surgery’.   

Human Microbiome Market worth $658 Million by 2023

OptiBiotix’s CEO Stephen OHara said ‘This report highlights the tremendous opportunity of the human microbiome with its growth potential being recognised by large corporate, food, health, and increasingly pharmaceutical companies. This creates multiple product and partnering opportunities for OptiBiotix across its two technology platforms. OptiBiotix is well placed to exploit the growing media, investor, and corporate interest in the microbiome and build a business with significant value for shareholders

Steven OHara comments on Daily Mail article referencing Statins

Stephen OHara, OptiBiotix’s CEO said: ‘Whilst this appears to be speculative reporting this article in the Mail reflects increasing concern about side affects from statins. Whilst many users will benefit from statins an increasing number are likely to look to for alternative treatment options.  There is growing interest in healthcare in the use of  agents which supplement existing treatment options in having mechanisms which work complementary to statins.  This creates the potential  to lower statin dosage, reduce cost, improve statin compliance and limit potential side effects.  This is likely to increase interest is products such as OptiBiotix’s cholesterol reducing microbial supplement’.

Stephen OHara, OptiBiotix’s CEO said: ‘This report in the Express is another article highlighting concerns from the side affects from statins.  This has created interest from healthcare providers in the use of  agents which replace or supplement existing treatment options: particularly where mechanisms of action work complementary to existing treatments.  OptiBiotix’s microbial strain has shown significant reduction in LDL cholesterol in clinical studies and has a mechanism of action complementary to statins.  This suggests combinational treatment may have the potential to lower statin dosage, reduce cost, and limit side effects whilst improving statin compliance’ 

Stephen OHara, OptiBiotix’s CEO said: ‘This news paper article reports on the role of the microbiome in weight loss. Whilst rather speculative it does reflect the growing scientific understanding on factors such as the microbiome which may be  influencing sustainable weight loss. The early evidence suggests that people with a greater microbial diversity  may be able to respond more quickly to dieting  and are more able to sustain weight loss than those with less microbial diversity.  People who have fast food diets tend to have a restricted microbial diversity and this study would suggest that losing and sustaining weight loss may be more difficult in these groups. GoFigure® products containing SlimBiome®, OptiBiotix’s patented formulation of ingredients developed by experts to support weight loss, includes a  prebiotic designed to enhance microbial diversity which this research suggests is likely to help people lose weight more quickly and sustain this weight loss. This creates the opportunity for easier and more sustainable weight loss than would be achieved with more traditional diets’.


Significant Shareholders

As at 23 November 2017, significant shareholders that hold more than 3% of the share capital of OptiBiotix Health Plc, and shareholdings of any other directors are detailed below:

  Number Ordinary Shares %
Stephen O'Hara (Director) 10,103,029 12.9
Finance Yorkshire Seedcorn Fund (FYSCF) 9,999,314 12.7

Stephen O'Hara holds 6,099,135 shares under Option

Innovation Centre

Innovation Way



YO10 5DG


Nominated Adviser

Cairn Financial Advisers LLP

61 Cheapside




Solicitors to the Company as to English law

Turner Parkinson LLP

Hollins Chambers

64a Bridge Street


M3 3BA


Reporting Accountants and Auditors

Jeffreys Henry LLP

5-7 Cranwood Street




Financial Public Relations

Walbrook PR Ltd

4 Lombard Street



Tel: 020 7933 8780

[email protected]




60 New Broad Street,




Intellectual Property Solicitors

Appleyard Lees

The Lexicon

Mount Street


M2 5NT



Share Registrars Limited

9 Lion and Lamb Yard



Columns Including OPTI


Market Reports Including OPTI

Video RSS



© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use